deep-vein thrombosis
Conditions
Interventions
Patients are assigned to receive twice-daily injection of enoxaparin sodium, in a 20-mg dose. Enoxaparin is initiated 24 to 36 hours after surgery until day 14.
Patients are assigned to receive twice
Sponsors
Department of orthopedic surgery, Tokyo women's medical university
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients are eligible for the study if they were 20 years of age or older and are scheduled for total knee arthroplasty or total hip arthroplasty.
Exclusion criteria
Exclusion criteria: We exclude patients with active bleeding or a high risk of bleeding that contraindicated the use of low-molecular-weight heparin and patients with any contraindication to the use of enoxaparin or cilostazol. Other exclusion criteria include conditions clinically significant compromised renal function, acute endocarditis, heparin induced thrombocytopenia, congestive heart failure, and pregnancy or breast-feeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The next day of surgery is defined as day 1.Deep-vein thrombosis is assessed on day 14 by mean of ultrasonography | — |
Countries
Japan
Contacts
Public Contactmorita yuji
Tokyo Women's Medical University Department of Orthopedic surgery
Outcome results
None listed